Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the ...

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin typesNew ...

Adults who suffer from the common disorder are significantly more likely to express suicidal thoughts, concerning new ...

First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough ...

An effort by President Trump’s administration to curb advertising for pharmaceutical drugs on television is posing a ...

While it has merit as a policy measure, it's the latest in a brutal series of administration actions that have hurt ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000 ®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to ...

Keratoconus has long been associated with atopic conditions like asthma, eczema and allergic conjunctivitis, and this ...